Hudson Bay Capital Management LP Amylyx Pharmaceuticals, Inc. Transaction History

Hudson Bay Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.71 $401,760 - $672,080	-248,000 Reduced 49.8%	250,000 $475,000
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $101,354 - $731,918	37,400 Added 8.12%	498,000 $1.41 Million
Q4 2023 Feb 14, 2024	SELL	$12.07 - $18.46 $2.67 Million - $4.09 Million	-221,623 Reduced 32.49%	460,600 $6.78 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $7.08 Million - $9.18 Million	391,323 Added 134.52%	682,223 $12.5 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $6.1 Million - $9.14 Million	290,900 New	290,900 $6.27 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $227M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.